{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-014700","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.511434+00:00","generated_at":"2026-05-19T12:31:58.611973+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GT Biopharma appoints new director, amends equity facility to raise up to $20M","bullets":["Andrew Ritter resigned from board effective June 9, 2025.","David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.","Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.","Equity facility remains at $20M; change gives more flexibility for future stock sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-014700","json":"https://secwatch.observer/filing/0001641172-25-014700.json","markdown":"https://secwatch.observer/filing/0001641172-25-014700.md","text":"https://secwatch.observer/filing/0001641172-25-014700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:31:58.611973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"264b5c329c","claim":"David C. Mun-Gavin was appointed as Non-employee Director and Chair of the Compensation Committee at GT Biopharma, Inc..","evidence_excerpt":"On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Non-employee Director and Chair of the Compensation Committee"}],"fact_type":"executive_change"},{"claim_id":"beb088f8a8","claim":"Andrew Ritter resigned as Member of the Board of Directors at GT Biopharma, Inc..","evidence_excerpt":"On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}